<DOC>
	<DOC>NCT00974311</DOC>
	<brief_summary>This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.</brief_summary>
	<brief_title>Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Progressive prostate cancer Medical or surgical castration with testosterone less than 50 ng/dl One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel ECOG performance status 02 Adequate bone marrow, hepatic, and renal function Able to swallow the study drug and comply with study requirements Informed consent Metastases in the brain or active epidural disease Another malignancy within the previous 5 years Clinically significant cardiovascular disease GI disorder affecting absorption</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castration-resistant</keyword>
</DOC>